Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

Scher, Gabrielle; Yankowski, Catherine; Kurup, Drishya; Josleyn, Nicole M.; Wilkinson, Eric R.; Wells, Jay; Steffens, Jesse; Lynn, Ginger; Vantongeren, Sean; Zeng, Xiankun; Twenhafel, Nancy; Cashman, Kathleen A.; Schnell, Matthias J.

doi:10.1038/s41541-024-00930-z

npj Vaccines

2024

DOI: 10.1038/s41541-024-00930-z

|View full text |Cite

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

Gabrielle Scher,

Catherine Yankowski,

Drishya Kurup

et al.

Help me understand this report

View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Current perspectives on vaccines and therapeutics for Lassa Fever

Warner,

Safronetz,

Stein

2024

Virol J

View full text Add to dashboard Cite

Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks. Several candidate vaccines have received support and have entered clinical trials with promising early results. This review focuses on the current state of vaccine and therapeutic development for LASV disease and the potential of these interventions to advance through clinical trials. The growing burden of LASV disease in Africa highlights the importance of advancing preclinical and clinical testing of vaccines and therapeutics to respond to the growing threat of LASV disease.

show abstract

Current perspectives on vaccines and therapeutics for Lassa Fever

Warner,

Safronetz,

Stein

2024

Virol J

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

Cited by 1 publication

References 58 publications

Current perspectives on vaccines and therapeutics for Lassa Fever

Current perspectives on vaccines and therapeutics for Lassa Fever

Contact Info

Product

Resources

About